Crisantaspase
Childhood Acute Myeloid Leukemia
Explore 46 assets in Childhood Acute Myeloid Leukemia →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Joanna Yi
Modality
protein_peptide
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07059975CT.gov UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Crisantaspase (this asset) | Joanna Yi | Early P1 | C · 39 |
| Etoposide | Joanna Yi | P3 | BBB |
| Cytarabine | Children's Oncology Group | P3 | BBB |
| Nivestim | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BBB |
| Methotrexate | Children's Oncology Group | P3 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P3 | BB |
| Idarubicin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BB |
| Cyclosporin A | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P3 | BB |
+42 more in the Childhood Acute Myeloid Leukemia cohort
Other indications for Crisantaspase
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Acute Lymphoblastic Leukemia | — | P3 | BB · 71 |
| Acute Lymphoblastic Leukemia | — | P4 | BB · 70 |
| Lymphoblastic Lymphoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Crisantaspase in Childhood Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/crisantaspase-childhood-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →